RE: Base at 345 before move up14 Apr 2021 11:01
Yes I saw that the other day , wasn't really sure what to think , other than since the bulk of sites are in UK , where steroids are standard of care , the number of patients eligible for IFN Beta1 just didn't make up enough to be assessed yet .
I spoke to the lady at REMAP a month ago about this , as was told that although the UK etc mostly have steroids , the drug was still open to sites that were not using steroid as a first care drug , ie other countries I guess .
They have now paused the domain , and we should get some read out on what they have with our drug soon ( going on the speed at which this happens , I'd say Q3 )
It may prove inconclusive , due to low numbers . Adaptive trials by their nature swing towards the drugs that are doing well ( steroids for example ) . That finding ( back in Sept 2020 ) , pretty much put us to the back of the queue in REMAP - which we all knew . Hence Faron continuing to get Hibsicus funded , and run under their own protocols to let the drug really get proven up .
I like many are actually focused on Bexmarilimab for 2021 . That news will blow away any negative Traumakine sentiment , which to be honest has already been reflected in the SP . That info has been sitting on REMAP website since the weekend , and the SP over on the Nas has actually gone up .